Impact of regular aspirin use on overall and cancer-specific survival in patients with colorectal cancer harboring a PIK3CA mutation

References

• Colorectal cancer incidence, mortality and prevalence worldwide in 2008 Summary, 2010. Available from: http://globocan.iarc.fr/factsheet.asp. Cited 15th September 2014.
   Google Scholar
• Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. New Engl J Med 2004;350:2335–42.
   PubMed Web of Science ®Google Scholar
• Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. New Engl J Med 2004;351:337–45.
   PubMed Web of Science ®Google Scholar
• Amado RG, Wolf M, Peeters M, Van Cutsem E, Siena S, Freeman DJ, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008;26:1626–34.
   PubMed Web of Science ®Google Scholar
• Karaca-Mandic P, McCullough JS, Siddiqui MA, Van Houten H, Shah ND. Impact of new drugs and biologics on colorectal cancer treatment and costs. J Oncol Pract 2011;7:e30s–7s.
   PubMedGoogle Scholar
• Tran B, Keating CL, Ananda SS, Kosmider S, Jones I, Croxford M, et al. Preliminary analysis of the cost-effectiveness of the National Bowel Cancer Screening Program: Demonstrating the potential value of comprehensive real world data. Intern Med J 2012;42:794–800.
   PubMed Web of Science ®Google Scholar
• Bardou M, Barkun A, Martel M. Effect of statin therapy on colorectal cancer. Gut 2010;59:1572–85.
   PubMed Web of Science ®Google Scholar
• Meyerhardt JA, editor. Beyond standard adjuvant therapy for colon cancer: Role of nonstandard interventions. Semin Oncol 2011: NIH Public Access.
   PubMed Web of Science ®Google Scholar
• Kerr DJ, Dunn JA, Langman MJ, Smith JL, Midgley RS, Stanley A, et al. Rofecoxib and cardiovascular adverse events in adjuvant treatment of colorectal cancer. New Engl J Med 2007;357:360–9.
   PubMed Web of Science ®Google Scholar
• Cole BF, Logan RF, Halabi S, Benamouzig R, Sandler RS, Grainge MJ, et al. Aspirin for the chemoprevention of colorectal adenomas: Meta-analysis of the randomized trials. J Natl Cancer Instit 2009;101:256–66.
   PubMed Web of Science ®Google Scholar
• Rothwell PM, Wilson M, Elwin C-E, Norrving B, Algra A, Warlow CP, et al. Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials. Lancet 2010;376:1741–50.
   PubMed Web of Science ®Google Scholar
• Ogino S, Lochhead P, Giovannucci E, Meyerhardt J, Fuchs C, Chan A. Discovery of colorectal cancer PIK3CA mutation as potential predictive biomarker: Power and promise of molecular pathological epidemiology. Oncogene 2014; 33:2949–55.
   PubMed Web of Science ®Google Scholar
• Liao X, Lochhead P, Nishihara R, Morikawa T, Kuchiba A, Yamauchi M, et al. Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival. New Engl J Med 2012;367: 1596–606.
   PubMed Web of Science ®Google Scholar
• Day FL, Jorissen RN, Lipton L, Mouradov D, Sakthianandeswaren A, Christie M, et al. PIK3CA and PTEN gene and exon mutation-specific clinicopathologic and molecular associations in colorectal cancer. Clin Cancer Res 2013;19:3285–96.
   PubMed Web of Science ®Google Scholar
• Ikenoue T, Kanai F, Hikiba Y, Obata T, Tanaka Y, Imamura J, et al. Functional analysis of PIK3CA gene mutations in human colorectal cancer. Cancer Res 2005;65:4562–7.
   PubMed Web of Science ®Google Scholar
• Rosty C, Young JP, Walsh MD, Clendenning M, Sanderson K, Walters RJ, et al. PIK3CA activating mutation in colorectal carcinoma: Associations with molecular features and survival. PloS One 2013;8:e65479.
   PubMed Web of Science ®Google Scholar
• Domingo E, Church DN, Sieber O, Ramamoorthy R, Yanagisawa Y, Johnstone E, et al. Evaluation of PIK3CA mutation as a predictor of benefit from nonsteroidal anti-inflammatory drug therapy in colorectal cancer. J Clin Oncol 2013;31:4297–305.
   PubMed Web of Science ®Google Scholar
• Reimers MS, Bastiaannet E, Langley RE, van Eijk R, van Vlierberghe RL, Lemmens VE, et al. Expression of HLA class I antigen, aspirin use, and survival after a diagnosis of colon cancer. JAMA Intern Med 2014;174:732–9.
   PubMed Web of Science ®Google Scholar
• De Berardis G, Lucisano G, D’Ettorre A, Pellegrini F, Lepore V, Tognoni G, et al. Association of aspirin use with major bleeding in patients with and without diabetes. JAMA 2012;307:2286–94.
   PubMed Web of Science ®Google Scholar
• Fenstermacher DA, Wenham RM, Rollison DE, Dalton WS. Implementing personalized medicine in a cancer center. Cancer J (Sudbury, Mass) 2011;17:528.
   PubMed Web of Science ®Google Scholar
• Tran B, Dancey JE, Kamel-Reid S, McPherson JD, Bedard PL, Brown AM, et al. Cancer genomics: Technology, discovery, and translation. J Clin Oncol 2012;30:647–60.
   PubMed Web of Science ®Google Scholar
• Roth GA, Gillespie CW, Mokdad AA, Shen DD, Fleming DW, Stergachis A, et al. Aspirin use and knowledge in the community: A population-and health facility based survey for measuring local health system performance. BMC Cardiovasc Disord 2014;14:16.
   PubMed Web of Science ®Google Scholar
• Giovannucci E, Rimm EB, Stampfer MJ, Colditz GA, Ascherio A, Willett WC. Aspirin use and the risk for colorectal cancer and adenoma in male health professionals. Ann Intern Med 1994;121:241–6.
   PubMed Web of Science ®Google Scholar
• Viudez A, Hernandez I, Vera R, de Navarra CH, Liao X, Lochhead P, et al. Aspirin, PIK3CA mutation, and colorectal-cancer survival. N Engl J Med 2013;368:289.
   PubMed Web of Science ®Google Scholar
• Pasche B. Differential effects of aspirin before and after diagnosis of colorectal cancer. JAMA 2013;309:2598–9.
   PubMed Web of Science ®Google Scholar